miRagen Therapeutics to Report Third Quarter 2019 Financial Results and Host a Conference Call
October 22, 2019 08:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Oct. 22, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...
miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth
October 16, 2019 02:45 ET
|
Miragen Therapeutics, Inc.
Data included in an oral presentation at the 15th annual meeting of the Oligonucleotide Therapeutics Society Data supports advancing MRG-110 into additional clinical studies BOULDER, Colo., Oct. ...
miRagen Therapeutics to Present a Corporate Overview at the Robert W. Baird & Co. 2019 Global Healthcare Conference
August 15, 2019 08:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Aug. 15, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...
miRagen Therapeutics to Present a Corporate Overview at the 2019 Wedbush Healthcare Conference
August 12, 2019 08:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Aug. 12, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...
miRagen Reports Second Quarter 2019 Results; Regains Global Rights to MRG-110 and Announces Corporate Restructuring
August 07, 2019 16:05 ET
|
Miragen Therapeutics, Inc.
miRagen to regain global rights to MRG-110 after Servier provides notice of portfolio realignment; expects to announce Phase 1 data during the second half of 2019Company anticipates reporting primary...
Miragen Therapeutics to Report Second Quarter 2019 Financial Results and Host a Conference Call on August 7th
July 24, 2019 08:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., July 24, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...
miRagen Therapeutics to Present a Corporate Overview at the Jefferies 2019 Global Healthcare Conference
May 28, 2019 16:30 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., May 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...
miRagen Presents Preclinical Data in Pulmonary Fibrosis Using Second Generation microRNA-29 Replacement Product Candidate at the 2019 American Thoracic Society International Conference
May 21, 2019 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., May 21, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 08, 2019 16:01 ET
|
Miragen Therapeutics, Inc.
Initiated patient dosing in the SOLAR Phase 2 trial for cobomarsen Released updated clinical data from the Phase 1 trial of cobomarsen in ATLL patientsReleased data from preclinical studies showing...
miRagen Therapeutics Announces New Data Supporting the Potential Use of Remlarsen to Prevent Corneal Fibrosis at the 2019 ARVO Meeting
April 29, 2019 07:00 ET
|
Miragen Therapeutics, Inc.
Preclinical data indicate that remlarsen accelerated the healing of corneal injury when compared to placebomiRagen believes the study’s results support that remlarsen may offer a novel therapeutic for...